FDA Investigator Dustin P Tran

Dustin P Tran has conducted inspections on 85 sites in 3 countries as of 03 Jan 2022. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
85
Last Inspection Date:
03 Jan 2022
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America, Philippines, Hungary
FDA Investigators that have inspected at least one site in common with Dustin P Tran:
Adam S Freeman, Alexandra M Cossi, Alexandria L Capuano, Alicia K Mckinsey, Alla Dubrovsky, Amanda E Lewin, PhD, Andrew E Kay, Andrew T Todd, Andrew W Harmon, Aneel K Sanghu, Angel K Sandhu, Angela D Wise, Anh M Lac, Anna J Vickrey, Ashar P Parikh, Bei Yu, Belinda E Clifton, Breena L D'ambrogi, Brian Ravitch, Bruce D Broidy, Candace Y Gomez Broughton, Capri R Woolridge, Carl Lee, Carol A Elems, Carolyn A Renshaw, CDR Rochelle B Young, RPh, MSA, Charles A Snipes, PhD, Christine M Parmentier, Christopher R Czajka, Christopher W Buser, Cynthia Jim, CSO, Cynthia L Ford, Daniel J Roberts, Darlene B Almogela, David G Eng, Deborah K Richardson, Debra Lboyd Seale, Dipti Kalra, Dolores Harper, Dr. Abhijit Raha, PhD, Dr. Mark J Seaton, PhD, Dr. Zhou Chen (nmi), MD PhD, Dustin R Abaonza, Dylan D Yao, MD, PhD, Edward D Harris, Edward D Vains, Eileen A Liu, Elizabeth H Slazak, Emal Wahab, Emmanuel Adu Gyamfi, PhD, Erin M Mcdowell, Evelyn Wong, Gene R Gunn, Gina M Hall, Gloria A Milster, Gulshan R Anand, Haley H Seymour, Hanna L Potter, Henry K Lau, Himanshu Gupta, PhD, Humberto Z Gomez, Hung H Do, MS, Ingrid A Zambrana, Jacqueline O Snell, James C Yee, Jane G Choi, Janet Pulver, Janice Wai, Jasmine Y Wang, Jeanmaire Hryshko, Jeanne A Young, Jeanne J Thai, Jeffrey M Watson, Jeffrey W Shrifter, DPM, Jennifer Crumb, Jennifer L Johnson, Jennifer S King, Jenny K Yee, Jessica B Darneille, Joan T Briones, Joanne M Schlossin, Jocelyn T Ramos, John A Gonzalez, Jolanna A Norton, Jonathan R Campos, Joseph A Seitz, III, Joseph Tibay, Joslyn K Brunelle, PhD, Juanita Banuelos, Juanj N Wu, Jude C Dikes, Kara A Scheibner, PhD, Karen M Montgomery (KMM), Kawshalya Pathiraja, Kelvin Cheung, Kevin P Foley, Kristi B Panzer, Kristin M Abaonza, Kula N Jha, Lan T Tran, Lance Mde Souza, MBA, Larkin R Buckalew, Laura Fontan, MS, Lauren E Swantko, LCDR Jennifer H Rhyu, Linda Linh N Adams, Linda S Shook, Linh Tu, Lourdes Andujar, Lucila B Nwatu, Mageet, Maida Henesian (NMI), Maridali Deleon Torres, Marie K Kinkade, Marissa J Chan, Marjorie D Santos, Mark C Saale, Marlo Ianm Alintanahin, Mary Ewilkerson Brinsko, Matthew R Clabeaux, Melkamu Getie Kebtie, PhD, Michelle L Tripp, Monique C Lo, Nathan R Moon, Paula A Trost, Peter E Baker, Prabhu P Raju, Randy L Elsberry, Raymond T Oji, Raymond W Brullo, Rebecca T Davis, Riley C Graham, Robles, Rumany C Penn, PharmD, Ruth A Williams, Said H Muse, Sajin Bae, Sandra S Saniga, Savannah E Samp, Scott N Lim, Shelley H Beausoleil, Sherri J Jackson, Stefanie R Cook, Stephanie A Slater, MS, Stephen T Hansen, Steven B Chiu, Steven C Himebaugh, Steven M Galvez, Stuart W Russell, Sunitha K Rajaram, PhD, Susan K Cummins, MD, MPA, Teena H Aiken, Terrence Gee, Terri E Gibson, Thea C Grome, Theressa B Smith, Thomas J Arista, Thomas R Withers, Thomas W Gordon, Uduak M Inokon, Uttaniti Limchumroon (Tom), Victoria Taylor, William J Weis, William V Millar, Xiaohan Cai, PhD, Ying Xin Fan, PhD, Yiyue Zhang (nmi), PhD

Dustin P Tran's Documents

Publish Date Document Type Title
April, 2019 FDA 483 BioSurg, Inc. - Form 483, 2019-04-19
July, 2020 EIR Adam S. Giermasz, M.D., Ph.D. - EIR, 2020-07-17
April, 2017 EIR David Miklos, MD - EIR, 2017-04-07
December, 2017 FDA 483 Philip D. Darney, M.D. - Form 483, 2017-12-01
April, 2021 FDA 483 May T. Cho, M.D. - Form 483, 2021-04-14
June, 2021 EIR Edward C. Hsiao, M.D., Ph.D. - EIR, 2021-07-07
June, 2019 FDA 483 Response Steiner Biotechnology LLC - Form 483R, 2019-06-28
March, 2016 FDA 483 Meditech Laboratories, Inc - Form 483, 2016-03-18
May, 2019 FDA 483 Comparative Biosciences, Inc - Form 483, 2019-05-17
January, 2018 FDA 483 Cordis Corporation - Form 483, 2018-01-12
February, 2018 EIR Pacific BioLabs - EIR, 2018-02-22
January, 2022 FDA 483 Elaine E. Tseng, M.D. - Form 483, 2022-01-28
February, 2020 FDA 483 BioMarin Pharmaceutical Inc. - Form 483, 2020-02-28
July, 2021 EIR Zogenix, Inc. - EIR, 2021-07-15
June, 2017 FDA 483 Paul Harmatz, M.D. - Form 483, 2017-06-16
January, 2016 FDA 483 Abbott's Compounding Pharmacy, Inc. - Form 483, 2016-01-08
June, 2019 FDA 483 Steiner Biotechnology LLC - Form 483, 2019-07-10
February, 2018 FDA 483 Jeffrey Ralph, M.D. - Form 483, 2018-02-09
June, 2021 FDA 483 Edward C. Hsiao, M.D., Ph.D. - Form 483, 2021-06-29
September, 2019 EIR Lovelace Biomedical Research Institute - EIR, 2019-09-13
November, 2018 EIR BioMarin Pharmaceutical Inc. - EIR, 2018-11-09
April, 2021 FDA 483 Innova Medical Group Inc. - Form 483, 2021-04-09
November, 2020 FDA 483 Michael L. Levin, M.D. - Form 483, 2020-11-25
May, 2019 FDA 483 Response Comparative Biosciences, Inc - Form 483R, 2019-06-06
February, 2020 EIR BioMarin Pharmaceutical Inc. - EIR, 2020-02-28
October, 2021 FDA 483 Leila Chaychi, M.D. - Form 483, 2021-10-22
May, 2021 EIR Mirum Pharmaceuticals, Inc. - EIR, 2021-05-12
July, 2017 FDA 483 Ron Gallemore, M.D., Ph.D. - Form 483, 2017-07-15
December, 2019 EIR Portola Pharmaceuticals, Inc. - EIR, 2019-12-17
September, 2019 FDA 483 Lovelace Biomedical Research Institute - Form 483, 2019-09-13

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more